免疫检查点抑制剂风湿性并发症的管理:风湿病学视角
随着免疫检查点抑制剂(ICI)适应证扩大,更多患者暴露于此类药物,免疫相关不良事件(irAEs)的管理成为挑战。风湿性/系统性irAEs虽似乎较少见(临床试验中可能漏报),但因其可能比其他irAEs持续更久,管理信息高度相关。本文基于临床试验数据但主要基于已发表的病例报告和系列,总结风湿性/系统性irAEs的管理,结合背景并提出治疗展望。
要点
- 风湿性/系统性irAEs可累及任何器官,但最常见影响皮肤、胃肠道和内分泌系统。
- 管理包括抗炎治疗(糖皮质激素、合成及生物免疫调节/免疫抑制药)、对症治疗及暂停或罕见停用ICI。
- 风湿性/系统性irAEs可能比其他irAEs持续更久,管理信息高度相关。
核心结论
- 风湿性/系统性irAEs的管理基于临床试验数据但主要来自病例报告和系列,包括抗炎治疗、免疫调节/免疫抑制及暂停或罕见停用ICI。
研究设计与样本
- 综述,基于临床试验数据但主要基于已发表的病例报告和系列,总结风湿性/系统性irAEs的管理。
主要发现
- 风湿性/系统性irAEs似乎较少见,但临床试验中可能漏报。
- 风湿性/系统性irAEs可累及任何器官或组织,但最常见影响皮肤、胃肠道和内分泌系统。
- 风湿性/系统性irAEs可能比其他irAEs持续更久。
临床怎么用
- 管理包括抗炎治疗如糖皮质激素、合成及生物免疫调节/免疫抑制药物、对症治疗,以及暂停或罕见停用ICI。
局限性
- 风湿性/系统性irAEs的信息主要来自病例报告和系列,临床试验中可能漏报。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since immune checkpoint inhibitors became the standard of care for an increasing number of indications, more patients have been exposed to these drugs and physicians are more challenged with the management of a unique spectrum of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors. Those irAEs of autoimmune or autoinflammatory origin, or both, can involve any organ or tissue, but most commonly affect the dermatological, gastrointestinal and endocrine systems. Rheumatic/systemic irAEs seem to be less frequent (although underreporting in clinical trials is probable), but information on their management is highly relevant given that they can persist longer than other irAEs. Their management consists of anti-inflammatory treatment including glucocorticoids, synthetic and biologic immunomodulatory/immunosuppressive drugs, symptomatic therapies as well as holding or, rarely, discontinuation of immune checkpoint inhibitors. Here, we summarize the management of rheumatic/systemic irAEs based on data from clinical trials but mainly from published case reports and series, contextualize them and propose perspectives for their treatment.
引用
- Leipe J, Mariette X. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. Rheumatology (Oxford). 2019. PMID: 31816078. doi:10.1093/rheumatology/kez360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。